Jiangsu Hengrui Medicine Co., Ltd.
Jiangsu Hengrui Medicine Co., Ltd., established in 1970, having over 13,000 employees globally, is the largest manufacturer of antineoplastics in China. Its operating income was over USD 1.7 billion in 2016. The company stock was officially listed on the Shanghai Stock Exchange in 2000. All APIs and finish dosage forms have passed national GMP authentication. For APIs, we got approvals from US-FDA, EDQM, PMDA and TGA. For FDFs, we got approvals from US-FDA, EU and PMDA.
Since its inception, holding “honest and trustworthy, quality first” business principles, Hengrui Medicine has been committed to innovative development and has created brand advantage in antineoplastics, surgical drugs, endocrine drugs, cardiovascular drugs, anti-infectives and other areas. Some products are exported to Europe, America and Japan. Sales of anticancer drugs and surgical drug ranked first domestically for many years.